Gilead Sciences, Inc. $GILD Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,367 shares of the biopharmaceutical company’s stock after selling 164 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Gilead Sciences were worth $262,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Nuveen LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC lifted its stake in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 8th. TD Cowen upped their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Price Performance

GILD stock opened at $120.94 on Friday. The business’s fifty day moving average price is $115.47 and its 200 day moving average price is $111.07. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $150.06 billion, a PE ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,500 shares of company stock worth $8,281,540. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.